SCOLR Pharma, Inc. Reports Third Quarter 2008 Financi...( Pivotal Phase III Trial Primary En...),Health

Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR's 12-Hour

Ibuprofen

BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today reported financial results for the three and nine months ended September 30, 2008. The Company will host a live conference call today, November 7, 2008, at 11:30 a.m. (Eastern Standard Time).

Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We had a very productive third quarter making significant progress advancing our lead product candidates and securing additional non-dilutive operating capital while maintaining financial discipline. Most importantly, yesterday we reported favorable top-line results from our pivotal Phase III trial to evaluate the safety and efficacy of our 12 hour CDT(R) 600 mg extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The trial incorporated FDA special protocol assessment design elements, met both co-primary endpoints (p<0.0001), and had no significant adverse events. This successful trial is an extremely important milestone for the Company. We expect that the successful results of this study will focus the attention of potential partners and facilitate an alliance for our lead product candidate."

Also during the quarter, SCOLR submitted an Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on our patented Controlled Delivery Technology (CDT(R)) platform. Subsequently, we reported that the U.S. FDA had accepted our submission for review. This is the first product approval application filed by SCOLR Pharma, and, if approved, would further demonstrate the novel advantages of our proprietary drug delivery technology. '/>"/>